CL2024002205A1 - Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento; usos de los mismos - Google Patents

Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento; usos de los mismos

Info

Publication number
CL2024002205A1
CL2024002205A1 CL2024002205A CL2024002205A CL2024002205A1 CL 2024002205 A1 CL2024002205 A1 CL 2024002205A1 CL 2024002205 A CL2024002205 A CL 2024002205A CL 2024002205 A CL2024002205 A CL 2024002205A CL 2024002205 A1 CL2024002205 A1 CL 2024002205A1
Authority
CL
Chile
Prior art keywords
spirocyclic
inhibitors
complement factor
piperidinyl derivatives
piperidinyl
Prior art date
Application number
CL2024002205A
Other languages
English (en)
Spanish (es)
Inventor
Simic Oliver
M Adams Christopher
C Czabaniuk Lara
Christoph Hediger Michael
Hurth Konstanze
LABBE-GIGUERE Nancy
LIMA Fabio
Patel Tajesh
Sendzik Martin
Vulpetti Anna
Flohr Stefanie
Gessier François
Vitrey Angela
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2024002205A1 publication Critical patent/CL2024002205A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024002205A 2022-01-24 2024-07-22 Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento; usos de los mismos CL2024002205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263302246P 2022-01-24 2022-01-24

Publications (1)

Publication Number Publication Date
CL2024002205A1 true CL2024002205A1 (es) 2025-01-10

Family

ID=85150566

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002205A CL2024002205A1 (es) 2022-01-24 2024-07-22 Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento; usos de los mismos

Country Status (16)

Country Link
US (1) US20250115572A1 (https=)
EP (1) EP4469157A1 (https=)
JP (1) JP2025504859A (https=)
KR (1) KR20240138095A (https=)
CN (1) CN118696035A (https=)
AU (1) AU2023209631A1 (https=)
CA (1) CA3247772A1 (https=)
CL (1) CL2024002205A1 (https=)
CO (1) CO2024009660A2 (https=)
CR (1) CR20240300A (https=)
DO (1) DOP2024000142A (https=)
IL (1) IL314186A (https=)
JO (1) JOP20240165A1 (https=)
MX (1) MX2024009062A (https=)
PE (1) PE20242005A1 (https=)
WO (1) WO2023139534A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途
TW202423426A (zh) * 2022-08-31 2024-06-16 美商奇努克醫療股份有限公司 經取代之吲哚化合物及其使用方法
IL320661A (en) * 2022-11-14 2025-07-01 Novartis Pharma Ag Solid forms of complement factor B inhibitors
TW202506657A (zh) * 2023-04-27 2025-02-16 大陸商上海翰森生物醫藥科技有限公司 一種哌啶基吲哚化合物的鹽及其製備方法
CN121889385A (zh) 2023-07-04 2026-04-17 希塔拉生物有限公司 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物
IL325760A (en) 2023-07-04 2026-03-01 Sitala Bio Ltd History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
AU2024324780A1 (en) * 2023-08-16 2026-02-05 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
TW202543599A (zh) * 2024-03-08 2025-11-16 大陸商江蘇豪森藥業集團有限公司 一種多元螺環化合物的晶型、其製備方法和醫藥用途
WO2025256600A1 (zh) * 2024-06-12 2025-12-18 润尔眼科药物(广州)有限公司 一种杂环化合物及其用途
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
RS66635B1 (sr) * 2017-08-31 2025-04-30 Novartis Ag Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
CN120081822A (zh) * 2021-06-03 2025-06-03 诺瓦提斯药物公司 经取代的吲哚化合物及其使用方法
EP4389742A4 (en) * 2021-08-18 2026-01-14 Xizang Haisco Pharmaceutical Co Ltd HETEROAROMATIC CYCLE DERIVATIVE CONTAINING BENZO NITROGEN AND ITS USE IN MEDICINE
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途

Also Published As

Publication number Publication date
JP2025504859A (ja) 2025-02-19
WO2023139534A1 (en) 2023-07-27
CR20240300A (es) 2024-08-23
KR20240138095A (ko) 2024-09-20
IL314186A (en) 2024-09-01
MX2024009062A (es) 2024-07-29
CO2024009660A2 (es) 2024-07-29
AU2023209631A1 (en) 2024-07-25
DOP2024000142A (es) 2024-08-30
US20250115572A1 (en) 2025-04-10
CA3247772A1 (en) 2023-07-27
PE20242005A1 (es) 2024-10-03
CN118696035A (zh) 2024-09-24
JOP20240165A1 (ar) 2024-07-24
EP4469157A1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
CL2024002205A1 (es) Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento; usos de los mismos
UY40204A (es) Inhibidores del Factor B del Complemento y Usos de los mismos
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
CO2022008092A2 (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
MX2024004921A (es) Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
CL2025000629A1 (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
AR123685A1 (es) Antagonistas del mrgx2
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
AR133953A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CL2021000329A1 (es) Compuestos útiles en terapia del vih
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2025010920A (es) Compuestos quimicos
DOP2010000064A (es) 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2023000670A1 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
BR112021017620A2 (pt) Compostos macrocíclicos
MX2017016370A (es) Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
AR132698A1 (es) DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN)
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4